NEUP
Neuphoria Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.31
+0.30%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2M | 1.2M | 15.6M | — | — |
| Cost of Revenue | 663.0K | 663.0K | 662.9K | 663.0K | 671.5K |
| Gross Profit | 511.2K | 511.2K | 15.0M | (663.0K) | (671.5K) |
| Operating Expenses | |||||
| R&D Expense | 6.0M | 3.5B | 9.0M | 14.1M | 19.7M |
| SG&A Expense | 9.6M | 7.4B | 7.8M | 8.5M | 13.4M |
| General & Admin Expense | 8.5M | 7.4B | 7.8M | 8.5M | 13.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (3.8M) | (11.0B) | (662.9K) | (4.7M) | — |
| Total Operating Expenses | 11.9M | 10.3M | 16.1M | 17.9M | 33.1M |
| Cost and Expenses | 12.2M | 11.0M | 16.8M | 17.9M | 33.1M |
| Operating Income (EBIT) | (13.9M) | (9.8M) | (1.1M) | (26.8M) | (33.1M) |
| Non-Operating | |||||
| Interest Income | 665.6K | 665.6K | 166.5K | 220.1K | 486.4K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 665.6K | 665.6K | 166.5K | 220.1K | 486.4K |
| Other Non-Op Income/Expense | (4.7M) | (3.8M) | 291.1K | 2.3M | 695.5K |
| Non-Operating Income (excl Interest) | (2.6M) | — | — | (142.5K) | (636.3K) |
| EBT (Pre-Tax Income) | (18.7M) | (13.6M) | (838.0K) | (15.6M) | (32.4M) |
| Income Tax Expense | (157.0K) | (139.2K) | (468.4K) | (87.3K) | (209.5K) |
| Bottom Line | |||||
| Net Income | (18.5M) | (13.5M) | (369.6K) | (15.5M) | (32.2M) |
| Earnings from Cont. Ops | (18.5M) | (13.5M) | (369.6K) | (15.5M) | (32.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.5M) | (13.5M) | (369.6K) | (15.5M) | (32.2M) |
| Per Share | |||||
| Basic EPS | ($7.26) | ($3.06) | ($0.23) | ($0.10) | ($0.24) |
| Diluted EPS | ($7.26) | ($3.06) | ($0.23) | ($0.10) | ($0.24) |
| Revenue Per Share | $0.22 | $0.27 | $9.64 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.4M | 4.4M | 1.6M | 149.8M | 122.4M |
| Diluted Shares Outstanding | 5.4M | 4.4M | 1.6M | 149.8M | 122.4M |
| Profitability Metrics | |||||
| EBITDA | (12.7M) | (9.1M) | (466.2K) | (26.0M) | (31.5M) |
| D&A | 663.0K | 663.0K | 662.9K | 663.0K | 970.7K |
| EBIT | (13.4M) | (9.8M) | (1.1M) | (26.6M) | (32.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026